DTP Branches and Offices
DTP History
| 1900–1925 |
 DTP EVOLUTION | transcript |
|---|---|
| 1926–1950 |
Mechlorethamine, ethinyl estradiol, TEM, mercaptopurine, methotrexate, busulfan |
| 1955 | |
| 1957 | |
| 1962 | |
| 1967 | |
| 1968 | |
| 1969 |
TAXOL | transcript |
| 1970 |
Multimodal therapy proven more effective than surgery alone in some cancers |
| 1971 | |
| 1975 |
Mouse P388 model adopted as primary screen Input at 15,000 per year Rational selection approach used |
| 1976 | |
| 1977 | |
| 1978 |
Biological Response Modifiers Program planning begins Average cost of preclinical development is $215,000 200 companies have signed discreet agreement CISPLATIN | transcript |
| 1979 |
Linear array becomes standard approach |
| 1980 |
17-AAG 330507 (Geldanamycin analog) received Cures against leukemias possible Lacking effective drugs for solid tumors in general |
| 1981 | |
| 1982 |
Mix of mouse and human tumors TUMOR PANEL | transcript |
| 1983 | |
| 1984 |
Taxol 125973 clinical trials begin DTP produces 1,000,000 injectable units per year |
| 1985 | |
| 1986 |
Halichondrin B 609395 received |
| 1989 | |
| 1990 |
Human tumor cell line assay adopted as primary screen Depsipeptide 630176 received |
| 1991 |
Natural products repository makes extracts available to researchers Depsipeptide 630176 presented to DN FLUDARABINE | transcript |
| 1992 |
Human tumor cell line panel revised to include breast and prostate cell lines Geldanamycin 122750 presented to DN Flavopiridol 649890 received and presented to DN Halichondrin B 609395 presented to DN |
| 1994 |
Benzothiazole 674495 parent received Flavopiridol 649890 clinical trials begin FLAVOPIRIDOL 649890 | transcript |
| 1995 |
Hollow fiber assay adopted as prerequisite for xenograft studies Biological Resources Branch integrated into DTP |
| 1996 |
Benzothiazole 674495 parent presented to DN Aminoflavone 686288 received Depsipeptide 630176 clinical trials begin BCNU 409962 (Gliadel Wafer) developed by NCDDG Yeast screening program begins at Fred Hutchinson Cancer Research Center |
| 1997 |
SJG-136 694501 received Velcade 681239 presented to DN Aminoflavone 686288 presented to DN |
| 1998 |
Mouse Models of Human Cancers Consortium 17-DMAG 707545 (Geldanamycin analog) received E7389 707389 (Halichondrin B analog) presented to DN Emphasis on extramural support “Open” repository of compounds created Input down to 3K in favor of molecular targets emphasis |
| 1999 |
Epothilone 703147 RAID project approved BL22 691237 clinical trial begins Velcade 681239 clinical trials begin Benzothiazole prodrug 710305 received Aminoflavone prodrug 710464 received SJG-136 694501 presented to DN 17-AAG 330507 clinical trials begin E7 Vaccine 723254 RAID project approved |
| 2000 |
Dynamic Molecular Targets Website launched, including first microarray data Decision Network (DN) changed to Drug Development Group (DDG) |
| 2001 |
Epothilone 703147 clinical trials begin Screening of 140,000 compounds in yeast screen completed R*A*N*D and IIP initiatives begin |
| 2002 |
Phortress 710305 (Benzothiazole prodrug) presented to DDG 17-DMAG 707545 presented to DDG E7389 707389 clinical trials begin Aminoflavone prodrug 710464 presented to DDG |
| 2003 |
SJG-136 694501 clinical trials begin Velcade 681239 receives NDA for multiple myeloma Phortress 710305 in clinical trials in the United Kingdom E7 Vaccine 723254 clinical trials begin |
| 2004 |
Academic Public Private Partnership Program (AP4) planning grants funded |
| 2005 |
Aminoflavone prodrug 710464 clinical trials begin DTP’s 50th anniversary |
| 2006 |
Reinventing drug development at NCI: PK/PD |
| 2015 |
FUTURE OF DTP | transcript NCI CHALLENGE GOAL | transcript |